These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26165756)

  • 21. Oritavancin. Eli Lilly & Co.
    Barrett JF
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1039-44. PubMed ID: 11892911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Glycopeptides].
    Hayashi I
    Nihon Rinsho; 2001 Apr; 59(4):761-70. PubMed ID: 11305003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.
    Arhin FF; Belley A; McKay GA; Moeck G
    Curr Protoc Microbiol; 2010 Feb; Chapter 17():Unit17.1. PubMed ID: 20131224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ; Drew RH
    Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-dose oritavancin in the treatment of acute bacterial skin infections.
    Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
    N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycopeptide antibiotics: back to the future.
    Butler MS; Hansford KA; Blaskovich MA; Halai R; Cooper MA
    J Antibiot (Tokyo); 2014 Sep; 67(9):631-44. PubMed ID: 25118105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.
    Zeng D; Debabov D; Hartsell TL; Cano RJ; Adams S; Schuyler JA; McMillan R; Pace JL
    Cold Spring Harb Perspect Med; 2016 Dec; 6(12):. PubMed ID: 27663982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.
    van Groesen E; Innocenti P; Martin NI
    ACS Infect Dis; 2022 Aug; 8(8):1381-1407. PubMed ID: 35895325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
    Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New antimicrobials against Gram-positive organisms].
    Montejo M
    Nefrologia; 2008; 28 Suppl 6():119-24. PubMed ID: 18957022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oritavancin--an investigational glycopeptide antibiotic.
    Ward KE; Mersfelder TL; LaPlante KL
    Expert Opin Investig Drugs; 2006 Apr; 15(4):417-29. PubMed ID: 16548791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties.
    Ślusarz R; Szulc M; Madaj J
    Carbohydr Res; 2014 May; 389():154-64. PubMed ID: 24685455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.